Research recently published in the seminal journal Gastroenterology failed to find evidence of alterations in key markers of bone formation and metabolism in postmenopausal women on PPI’s. The study examined calcium absorption, serum or urine mineral levels, parathyroid hormone, Vitamin D status, or bone-mineral density with 6 months of PPI therapy. The prospective double-blind study
Proton pump inhibitor therapy is not connected to an increased risk of cardiovascular disease, according to a study published in Alimentary Pharmacology & Therapeutics. The FDA has discouraged using PPI’s with antiplatelet therapy clopidogrel because the drugs work with the same isoenzyme. “Inhibition of CYP2C19 by PPIs may reduce the bioavailability of the active metabolites of
GERD affects 10% to 20% of adults in Western populations and has been known to be an increased risk factor for esophageal adenocarcinoma. Research on the association between antireflux medication or surgery and risk for esophageal adenocarcinoma has remained limited, although the typical approach has been to treat reflux aggressively when there are precancerous changes like
Several articles have shown an increased risk of fractures with PPI use as patients get older. Sanna Torvinen-Kiiskinen, PhD, of Kuopio Research Centre of Geriatric Care at the University of Eastern Finland, and colleagues wrote that an association between proton pump inhibitor (PPI) use and risk for fractures remains unclear due to contradictory study findings, and
Experts say even though studies have linked proton pump inhibitor use to multiple health problems, the scientific evidence overall is weak, which should help providers reassure concerned patients and avoid unnecessary discontinuation of PPI use. The attention on PPI safety, however, does offer an opportunity for practitioners to discuss limiting use of the drugs because
